ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Yingyi Wang
Matched on ORCID iD 0000-0003-1704-4643; OpenAlex author ID A5087251992. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper
Papers 5
- The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s11764-023-01429-7↗
- A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenoca… Co-author DOI 10.1186/s12885-023-11464-3↗
- Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0189↗
- Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data. Co-author DOI 10.1016/j.neo.2022.100841↗
- High Cancer Susceptibility Candidate 8 Expression Is Associated With Poor Prognosis of Pancreatic Adenocarcinoma: Validated Analysis Based on Four Cancer Datab… Co-author DOI 10.3389/fcell.2020.00392↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hui Jun Tang · 4 shared papers, 2022–2024 · strength 0.76
- Paper A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line … DOI 10.1186/s12885-023-11464-3↗
- Paper Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic … DOI 10.20892/j.issn.2095-3941.2023.0189↗
- Paper The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. DOI 10.1007/s11764-023-01429-7↗
- Yuejuan Cheng · 4 shared papers, 2022–2024 · strength 0.76
- Paper A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line … DOI 10.1186/s12885-023-11464-3↗
- Paper Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic … DOI 10.20892/j.issn.2095-3941.2023.0189↗
- Paper The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. DOI 10.1007/s11764-023-01429-7↗
- Chunmei Bai · 4 shared papers, 2022–2024 · strength 0.76
- Paper A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line … DOI 10.1186/s12885-023-11464-3↗
- Paper Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic … DOI 10.20892/j.issn.2095-3941.2023.0189↗
- Paper The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. DOI 10.1007/s11764-023-01429-7↗
- Tingting You · 2 shared papers, 2023–2024 · strength 0.40
- Paper A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line … DOI 10.1186/s12885-023-11464-3↗
- Paper The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. DOI 10.1007/s11764-023-01429-7↗
- Zhou Zhu · 1 shared paper, 2023 · strength 0.20
- Menghua Dai · 1 shared paper, 2022 · strength 0.16
- Taiping Zhang · 1 shared paper, 2022 · strength 0.16
- Junchao Guo · 1 shared paper, 2022 · strength 0.16
- Yuemei Yang · 1 shared paper, 2020 · strength 0.13
- Yu Pei Xiao · 1 shared paper, 2020 · strength 0.13
- Wenze Wang · 1 shared paper, 2020 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.